Company news
Madrigal Pharmaceuticals, Inc. news in 2022
Madrigal Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
December 20, 2022
Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis
December 18, 2022
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NASH Study of Resmetirom on Monday, December 19th
December 17, 2022
Madrigal Pharmaceuticals Provides an Overview of Upcoming Resmetirom Data Presentations and Reports 2022 Third Quarter Financial Results
November 2, 2022
Madrigal Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 6, 2022
Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis
August 30, 2022
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 Second Quarter Financial Results
August 3, 2022
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™
June 24, 2022
Madrigal Pharmaceuticals Supports International NASH Day on June 9
June 5, 2022
Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results
May 8, 2022
Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9
April 27, 2022
Madrigal Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
March 8, 2022
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results
February 23, 2022
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health
January 30, 2022
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31st
January 29, 2022
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics Officer
January 9, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (January 2022)
Technical · 15 slides · Jan 31, 2022